GB0100119D0 - Materials and methods relating to protein aggregation in neurodegenerative disease - Google Patents

Materials and methods relating to protein aggregation in neurodegenerative disease

Info

Publication number
GB0100119D0
GB0100119D0 GBGB0100119.7A GB0100119A GB0100119D0 GB 0100119 D0 GB0100119 D0 GB 0100119D0 GB 0100119 A GB0100119 A GB 0100119A GB 0100119 D0 GB0100119 D0 GB 0100119D0
Authority
GB
United Kingdom
Prior art keywords
protein aggregation
materials
neurodegenerative disease
methods relating
prognostic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0100119.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Aberdeen
Original Assignee
University of Aberdeen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Aberdeen filed Critical University of Aberdeen
Priority to GBGB0100119.7A priority Critical patent/GB0100119D0/en
Publication of GB0100119D0 publication Critical patent/GB0100119D0/en
Priority to PT02734847T priority patent/PT1348029E/pt
Priority to JP2002559452A priority patent/JP4580618B2/ja
Priority to EP02734847A priority patent/EP1348029B1/en
Priority to CA2433535A priority patent/CA2433535C/en
Priority to ES02734847T priority patent/ES2382457T3/es
Priority to HK03108778.8A priority patent/HK1056574B/en
Priority to DK02734847.3T priority patent/DK1348029T3/da
Priority to PCT/GB2002/000005 priority patent/WO2002059150A2/en
Priority to AU2002217310A priority patent/AU2002217310B2/en
Priority to US10/451,367 priority patent/US7834237B2/en
Priority to AT02734847T priority patent/ATE548453T1/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
GBGB0100119.7A 2001-01-03 2001-01-03 Materials and methods relating to protein aggregation in neurodegenerative disease Ceased GB0100119D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB0100119.7A GB0100119D0 (en) 2001-01-03 2001-01-03 Materials and methods relating to protein aggregation in neurodegenerative disease
AT02734847T ATE548453T1 (de) 2001-01-03 2002-01-02 Material und methoden, involviert in die protein- aggregation neurodegenerativer krankheiten
CA2433535A CA2433535C (en) 2001-01-03 2002-01-02 Materials and methods relating to protein aggregation in neurodegenerative disease
JP2002559452A JP4580618B2 (ja) 2001-01-03 2002-01-02 神経変性疾患におけるタンパク質凝集に関する材料および方法
EP02734847A EP1348029B1 (en) 2001-01-03 2002-01-02 Materials and methods relating to protein aggregation in neurodegenerative disease
PT02734847T PT1348029E (pt) 2001-01-03 2002-01-02 Materiais e métodos relativos a agregação de proteínas em doenças neurodegenerativas
ES02734847T ES2382457T3 (es) 2001-01-03 2002-01-02 Materiales y procedimientos relacionados con la agregación de proteínas en enfermedades neurodegenerativas
HK03108778.8A HK1056574B (en) 2001-01-03 2002-01-02 Materials and methods relating to protein aggregation in neurodegenerative disease
DK02734847.3T DK1348029T3 (da) 2001-01-03 2002-01-02 Materialer og fremgangsmåder involveret i proteinaggregering i neurodegenerative sygdomme
PCT/GB2002/000005 WO2002059150A2 (en) 2001-01-03 2002-01-02 Materials and methods relating to protein aggregation in neurodegenerative disease
AU2002217310A AU2002217310B2 (en) 2001-01-03 2002-01-02 Materials and methods relating to protein aggregation in neurodegenerative disease
US10/451,367 US7834237B2 (en) 2001-01-03 2002-01-02 Materials and methods relating to protein aggregation in neurodegenerative disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0100119.7A GB0100119D0 (en) 2001-01-03 2001-01-03 Materials and methods relating to protein aggregation in neurodegenerative disease

Publications (1)

Publication Number Publication Date
GB0100119D0 true GB0100119D0 (en) 2001-02-14

Family

ID=9906201

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0100119.7A Ceased GB0100119D0 (en) 2001-01-03 2001-01-03 Materials and methods relating to protein aggregation in neurodegenerative disease

Country Status (11)

Country Link
US (1) US7834237B2 (cg-RX-API-DMAC7.html)
EP (1) EP1348029B1 (cg-RX-API-DMAC7.html)
JP (1) JP4580618B2 (cg-RX-API-DMAC7.html)
AT (1) ATE548453T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002217310B2 (cg-RX-API-DMAC7.html)
CA (1) CA2433535C (cg-RX-API-DMAC7.html)
DK (1) DK1348029T3 (cg-RX-API-DMAC7.html)
ES (1) ES2382457T3 (cg-RX-API-DMAC7.html)
GB (1) GB0100119D0 (cg-RX-API-DMAC7.html)
PT (1) PT1348029E (cg-RX-API-DMAC7.html)
WO (1) WO2002059150A2 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0104685D0 (en) * 2001-02-26 2001-04-11 Leuven K U Res & Dev Tau-opathy model
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
GB0117326D0 (en) 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
WO2004007722A2 (en) * 2002-07-12 2004-01-22 Axon Neuroscience Forschungs- Und Entwicklungs Gmbh Transgenic animal expressing alzheimer’s tau protein
EP1516930A1 (en) * 2003-09-16 2005-03-23 Georg-August Universität Göttingen Cellular model of tauopathies for lead identification and drug discovery
DE602005016537D1 (de) * 2004-03-31 2009-10-22 Anges Mg Inc Testverfahren zur identifizierung eines kandidatenarzneistoffs
ES2770067T3 (es) 2004-05-11 2020-06-30 Ncardia Ag Descubrimiento de fármacos basado en células diferenciadas in vitro
JP5186212B2 (ja) 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物(mtc)などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
WO2007066809A1 (ja) * 2005-12-06 2007-06-14 Tokyo Metropolitan Organization For Medical Research タンパク質重合体の重合核となりうるタンパク質又はその重合体が導入された細胞及びその製造法
DK2004155T3 (en) 2006-03-29 2018-04-30 Wista Lab Ltd PROTEIN AGGREGATION INHIBITORS
CN104119294B (zh) 2006-03-29 2018-10-30 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物的制备方法
PT2954932T (pt) 2007-10-03 2018-12-12 Wista Lab Ltd Utilização terapêutica de diaminofenotiazinas
WO2012106363A2 (en) 2011-01-31 2012-08-09 Intellect Neurosciences Inc. Treatment of tauopathies
KR101888713B1 (ko) 2011-02-11 2018-08-14 위스타 레보레이토리스 리미티드 페노티아진 디아미늄 염 및 이의 용도
WO2012162179A1 (en) 2011-05-20 2012-11-29 Oligomerix, Inc. Tau protease compositions and methods of use
PL3487505T3 (pl) 2016-07-25 2023-10-09 Wista Laboratories Ltd. Podawanie i dawkowanie diaminofenotiazyn
CN111094327A (zh) * 2017-08-16 2020-05-01 Lgv1有限公司 Bpifb4蛋白的用于神经元疾病和损伤的vtft同种型
CN113874078B (zh) 2019-04-05 2025-05-06 Tauc3生物制品有限公司 抗tauc3抗体及其应用
GB201909454D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
CN113943766B (zh) * 2021-11-26 2024-01-26 守正创新生物科技(天津)有限公司 一种抗糖化寡肽-5(AdP)的制备及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE569430A (cg-RX-API-DMAC7.html) 1957-07-17
GB8724412D0 (en) 1987-10-19 1987-11-25 Medical Res Council Protein
US5571666A (en) 1988-10-28 1996-11-05 Oklahoma Medical Research Foundation Thiazine dyes used to inactivate HIV in biological fluids
JPH0725786A (ja) 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
US5912410A (en) 1990-06-15 1999-06-15 Scios Inc. Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease
CA2110488A1 (en) 1991-07-10 1993-01-21 Franceska Fieuws Fluorochemical water- and oil-repellent treating compositions
WO1993003369A1 (en) 1991-08-01 1993-02-18 Voorheis Paul H Diagnostic method for alzheimer's disease
WO1993011231A1 (en) 1991-12-06 1993-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tools for the diagnosis and treatment of alzheimer's disease
GB9316727D0 (en) 1993-08-12 1993-09-29 Inst Of Psychiatry Models of alzheimers's disease
GB9317193D0 (en) 1993-08-18 1993-10-06 Zeneca Ltd Method
FR2722695B1 (fr) 1994-07-22 1997-04-25 Demic Lab Sa Ustensile de badigeonnage cutane par frottement a usage medical
WO1996004915A1 (en) 1994-08-08 1996-02-22 Albert Einstein College Of Medicine Of Yeshiva University Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
DE4430091A1 (de) 1994-08-25 1996-02-29 Bayer Ag Verwendung von N-substituierten Phenothiazinen
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5804601A (en) 1995-04-10 1998-09-08 Takeda Chemical Industries, Ltd. Aromatic hydroxamic acid compounds, their production and use
US5898094A (en) 1996-10-21 1999-04-27 University Of South Florida Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
WO1999062548A1 (en) 1998-06-01 1999-12-09 Advanced Research And Technology Institute Methods and compositions for diagnosing tauopathies
DE19920514A1 (de) * 1999-05-05 2000-11-16 Boehringer Ingelheim Pharma Methoden zur Auffindung von Proteasen, die spezifisch membrangebundene Substrate spalten
WO2001053340A2 (en) 2000-01-21 2001-07-26 Pharmacia & Upjohn Company Transgenic mouse model of human neurodegenerative disease
JP2001352860A (ja) * 2000-06-15 2001-12-25 Inst Of Physical & Chemical Res 老年期痴呆症で生じる神経原線維変化を示すマウス
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
GB0117326D0 (en) 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
US20030217370A1 (en) 2002-05-16 2003-11-20 Giasson Benoit I. Transgenic animal expressing alpha-synuclein and uses thereof
US6953974B2 (en) * 2003-08-26 2005-10-11 Texas Instruments Incorporated EEPROM device and method for providing lower programming voltage
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
WO2006032879A2 (en) 2004-09-23 2006-03-30 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc)

Also Published As

Publication number Publication date
AU2002217310B2 (en) 2007-09-20
JP2004531224A (ja) 2004-10-14
WO2002059150A2 (en) 2002-08-01
PT1348029E (pt) 2012-06-15
DK1348029T3 (da) 2012-05-29
CA2433535A1 (en) 2002-08-01
CA2433535C (en) 2011-02-15
EP1348029B1 (en) 2012-03-07
HK1056574A1 (en) 2004-02-20
ES2382457T3 (es) 2012-06-08
US20040078835A1 (en) 2004-04-22
JP4580618B2 (ja) 2010-11-17
WO2002059150A3 (en) 2002-12-05
EP1348029A2 (en) 2003-10-01
US7834237B2 (en) 2010-11-16
ATE548453T1 (de) 2012-03-15

Similar Documents

Publication Publication Date Title
DK1348029T3 (da) Materialer og fremgangsmåder involveret i proteinaggregering i neurodegenerative sygdomme
WO2005061545A3 (en) Nogoa antibodies for the treatment of alzheimer disease
EP1409544A4 (en) HUMAN DR4 ANTIBODIES AND ITS APPLICATIONS
PT1625403E (pt) Método para a previsão, diagnóstico e diagnóstico diferencial de doença de alzheimer
AU8448301A (en) Remedies for heart failure
CR8108A (es) Tratamiento con anticuerpos anti-vegf
FI963101A7 (fi) Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoo n, joissa seerumin interleukiini-6-taso on kohonnut
WO2009027105A3 (en) Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
DE69841653D1 (de) Katalytische monoklonale antikörper mit proteaseaktivität zur selektiven lysis der proteinkomponente von mit pathologischen konditionen zusammenhängenden plaques und aggregaten
WO2000078813A3 (en) Huntington disease cellular model: stably transfected pc12 cells expressing mutant huntingtin
ATE522230T1 (de) Biphenyle als bilderzeugungsmittel bei der alzheimerschen krankheit
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
PL350620A1 (en) Diagnosis of a person's risk for developing atherosclerosis or diabetic retinopathy
EP1321153A4 (en) DRUG SUBSTANCES INTENDED FOR INTERSTITIAL PNEUMONIA, METHOD OF CONSTRUCTING AN ANIMAL MODEL OF THE DISEASE, AND SCREENING METHOD USING THE SAME
WO2003036261A3 (en) Drug development by rapid neuroimaging of neural cells
IT1299201B1 (it) Fibroblasti modificati geneticamente e loro uso
Caterson Immunological aspects of markers of joint disease
WO2006029838A3 (en) Secreted polypeptide species involved in alzheimer’s disease
IL172690A0 (en) Methods for the diagnosis and prognosis of alzheimer's disease
WO2002074921A3 (en) Methods for isolating proteins expressed by dendritic cells
AU2001289930A1 (en) Method for the production of human antibodies, antibodies thus obtained and their use in therapy and diagnosis
WO2004064768A3 (en) Animal model for alzheimer's disease
AU2002316158A1 (en) Methods and compounds for the diagnosis of inflammatory disease and identification of pharmacological agents
EP1573048A4 (en) IN CANCER EXPRESSED BRUSH SPECIFIC PROTEIN AND METHOD OF USE THEREOF
PT1496884E (pt) Associacao de um antitrombotico e de aspirina e sua utilizacao no tratamento das doencas tromboticas aterosclerosas.

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)